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Protein transduction domains (PTDs) are reagents
that facilitate the delivery of diverse cargo to the
interior of mammalian cells. We identified a PTD
called ‘‘Ypep’’ (N-YTFGLKTSFNVQ-C), with cell
penetration selectivity and potency profiles that are
tightly controlled by multivalency effects. Pentava-
lent display of Ypep on M13 bacteriophage enables
selective uptake of this phage in PC-3 human
prostate cancer cells at low picomolar concentra-
tion and in the presence of human blood. All
Ypep-dependent delivery is nontoxic and proceeds
through energy-dependent endocytosis. Collec-
tively, our results establish Ypep-displaying phage
as a cell-penetrating platform with selectivity and
potency profiles that compare to, or exceed, anti-
bodies and their fragments. Our findings may have
broader implications on the design of PTD technolo-
gies generated fromphage display, aswell as the use
of Ypep-displaying phage as a prostate cancer cell-
selective delivery platform.
INTRODUCTION
Macromolecular biopolymers, nanometer-sized materials, and
bacteriophage offer unique opportunities for advances in bio-
imaging and medicine (Boisselier and Astruc, 2009; Ghosh
et al., 2012; Leader et al., 2008; McGregor, 2008; Thorek et al.,
2006). Perhaps the most important impediment to their broader
use is the difficulties associated with the potent delivery of
these reagents across the lipid bilayer membrane of mammalian
cells (Torchilin and Lukyanov, 2003). Various technologies have
been developed that address challenges in the delivery of large
cargos to mammalian cells. These generally include liposomes
(Gregoriadis, 1995), lipid-linked compounds (Zelphati et al.,
2001), fusions to cell-surface receptor ligands (Gabel and Foster,
1986; Rizk et al., 2009), and supercharged proteins (Cronican
et al., 2010, 2011; McNaughton et al., 2009).
One promising approach for the delivery of macroscopic
cargo to mammalian cells is attachment with a protein transduc-434 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 Elsevietion domain (PTD). PTDs are short peptides (typically <20 amino
acids) that promote the internalization of cargo in mammalian
cells (Deshayes et al., 2005; Ford et al., 2001; Ma¨e and Langel,
2006). Although PTDs promote general transmembrane trans-
port, virtually every strategy to identify and combat disease
can be improved by selective delivery of cargo specifically to
diseased cells. The most common method for targeting cargo
to a specific cell is through fusion to a monoclonal antibody
or its fragment antigen-binding region (Fab fragment), which
binds a receptor present on the targeted cell. Although such
immunoconjugate-targeted therapies are often cell-selective,
they do not directly address the problem of cell internalization.
Further, their production, distribution, and storage are very
costly (Hughes, 2010; Wu and Senter, 2005). Unfortunately,
commercially available and commonly used polycationic PTDs,
such as the HIV-1 transactivator of transcription (Tat) peptide
(Frankel and Pabo, 1988; Green and Loewenstein, 1988), the
Drosophila Antennapedia-derived penetratin peptide (Derossi
et al., 1994), and polyarginine (Dubikovskaya et al., 2008; Fuchs
and Raines, 2005), although simple to use, do not selectively
penetrate diseased cells, and their potency of uptake is relatively
moderate to poor.
An ideal delivery platform would combine the cell selectivity of
antibodies with the membrane transport capability and ease of
production of PTDs. As part of a broader research program
focused on new methods to identify (image) and treat prostate
cancers, we set out to generate a prostate cancer cell-selective
PTD. The prostate-specific membrane antigen (PSMA) is a
membrane-bound glycoprotein that is restricted to the prostate.
Previously, studies analyzing the expression of PSMA have
found an upregulation in correlation with prostate cancer (Bost-
wick et al., 1998; Lapidus et al., 2000). Unsurprisingly, targeted
delivery of cargo to prostate cancer cells often relies on anti-
bodies, Fab fragments (Henry et al., 2004; Nanus et al., 2003;
Patri et al., 2004), or other ligands, such as aptamers (Dassie
et al., 2009), that bind PSMA. However, the expression level
of PSMA varies drastically among prostate cancer cells, and
many prostate cancer cells do not express PSMA (Murphy
et al., 1998;Wright et al., 1995). Therefore, in addition to targeted
delivery platforms, which extend beyond the antibody paradigm,
reagents that selectively target PSMA-negative prostate cancer
cells are required.
Bacteriophage (phage) evolution has been used to identify
PTDs not found in nature (Gao et al., 2002; Ivanenkov et al.,r Ltd All rights reserved
Figure 1. Screening for a PC-3 Prostate
Cancer Cell-Selective Protein Transduction
Domain
Phage are incubated with PC-3 prostate cancer
cells enriched for cell penetration. Cell-penetrating
phage are then incubated with a polyanionic tissue
culture plate, and phage that do not bind the tissue
culture plate are enriched. See also Figures S1 and
S8 available online.
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Multivalency Effects Control Cell Uptake1999; Kim et al., 2006; Nomura et al., 2007). We began by per-
forming consecutive rounds of positive selections to enrich
phage that penetrate PC-3 cells, a human prostate cancer cell
line with high metastatic potential (Pulukuri et al., 2005) that
does not express significant levels of PSMA (PSMA-neg) (Ghosh
et al., 2005), and remove phage that do not penetrate the four off-
target cell lines described below. After three rounds of positive
and negative selection, only phage with modest potency of
uptake and very poor cell selectivity were enriched. Changing
the order of the selection (positive to negative or negative to
positive) did not change the outcome. One possible reason for
this undesired outcome is the selection strategy itself. In this
scheme, ‘‘winners’’ may be phage with poor uptake efficiencies
in both targeted and untargeted cells. This phage would be ex-
pected to barely survive both the positive and negative selection.
Based on our initial results, wemodified the positive and nega-
tive selection to enrich for phage that potently penetrate targeted
PC-3 cells and remove polycationic PTD, which should not
be cell selective. From this selection, we identified phage that
display five copies of a linear 12-amino-acid peptide on the
N terminus of phage minor coat protein 3 (p3). This peptide
is referred to as ‘‘Ypep’’ (N-YTFGLKTSFNVQ-C) throughout.
Our data show that multivalency effects dramatically tune the
potency and, perhaps more importantly, the cell selectivity of
Ypep uptake. When cells are treated with a solution containing
5 mM GFP equipped with a single N-terminal Ypep peptide
(Ypep-GFP), 4-, 5-, and 8-fold more Ypep-GFP penetrate
targeted PC-3 cells than off-target LNCaP (PSMA-positive
prostate cancer [Israeli et al., 1994]), Hs 697.Sp (human spleen)
cells, and HEK293T (human embryonic kidney), respectively. We
observe 40% more GFP in targeted PC-3 cells following treat-
ment with 5 mM Ypep-GFP, compared to off-target MRC-9
human lung cells. The N termini and C termini of folded GFP
are proximal and are therefore spatially arranged in such a way
as to facilitate multivalent interactions between the termini of
GFP and a receptor, making this protein well suited to examine
the role multivalency effects play in uptake. When Ypep is fused
to the N termini and C termini of GFP (Ypep-GFP-Ypep), the
potency of GFP delivery increased 29-fold in targeted PC-3
cells. Perhaps more importantly, multivalency effects also con-
trol the cell selectivity of cell penetration. The cell selectivity
profiles of Ypep-GFP and Ypep-GFP-Ypep for targeted PC-3
cells over off-target LNCaP, HEK293T, and Hs 697.Sp cells
were similar. However, 3.8-fold more Ypep-GFP-Ypep pene-
trated PC-3 cells than off-target MRC-9 cells. GFP bearing twoChemistry & Biology 20, 434–444, March 21, 2013N-terminal copies of Ypep on its N
terminus ((Ypep)2-GFP) penetrates PC-3
cells with similar potency. M13 phagethat display five copies of Ypep on the N terminus ofminor phage
coat protein 3 ((Ypep)5-phage) recognize and penetrate targeted
PC-3 prostate cancer cells potency and selectivity profiles that
meet or exceed those typically associated with antibodies and
antibody fragments.BothYpep-GFPandYpep-GFP-Ypeppene-
trate PC-3 prostate cancer cells via caveolae/lipid-raft-mediated
endocytosis; (Ypep)5-phage delivery occurs through energy-
dependent endocytosis, and all Ypep-dependent delivery is
inhibited by addition of heparin sulfate, suggesting that Ypep-
dependent internalization requires interaction(s) with one or
morecell surfaceglycosaminoglycans.Deliveryof all Ypepconju-
gates is nontoxic under the conditions required for uptake. Both
Ypep-GFP-Ypep and (Ypep)5-phage penetrate PC-3 cells in
the presence of human blood. Collectively, our findings reveal
Ypep as a PTD with cell selectivity and potency profiles that are
tightly controlled by multivalency effects. Our results may have
broader application in the useof (Ypep)5-phage as a cell-targeted
delivery vehicle, aswell as the design of PTD-based technologies
that are generated using phage display evolution.
RESULTS AND DISCUSSION
Phage Display In Vitro Evolution of a Protein
Transduction Domain Platform Targeting PC-3 Prostate
Cancer Cells
As summarized in Figure 1, the selection involved incubating the
phage library with a monolayer of PC-3 prostate cancer cells. In
order to assure that only internalized phage were selected and
enriched, as opposed to phage that simply bound to the surface
of PC-3 cells, an extensive washing protocol was developed
from components of numerous literature reports (Gao et al.,
2002; Ivanenkov et al., 1999; Kim et al., 2006). Media containing
phage without affinity for PC-3 cells was removed, and the cells
were washed five times with PBS and then three times with Tris-
buffered saline (TBS)/0.1% Tween-20 solution. Cells were then
treated with a solution containing 3 mg/ml subtillisin in TBS for
40 min at 4C, which removed any remaining cell-surface-bound
phage by proteolytic degradation of the phage coat proteins
and/or human cell surface proteins involved in the phage-
cell interaction. Following the subtillisin treatment, cells were
washed three times with PBS containing a protease inhibitor
cocktail and pelleted by centrifugation. Titering from the final
PBS wash solution after subtillisin treatment showed that no
cell-surface-bound phage were present, indicating that the
washing scheme removed all phage that did not penetrate theª2013 Elsevier Ltd All rights reserved 435
Figure 2. Comparing Internalized Ypep-
GFP to Ypep-GFP-Ypep in PC-3 Cells
(A) Amounts of internalized GFP in PC-3 cells after
treatment with 0.5, 1, 5, or 10 mM Ypep-GFP.
Values and error bars represent the mean and SD
of three independent experiments.
(B) Fluorescence microscopy image of PC-3 cells
after a 1 hr treatment with 10 mM Ypep-GFP and
subsequent washing with PBS containing 20 U/ml
heparin sulfate. All images were taken using a
500 ms exposure. Lamp intensity was set at 20%
for all images.
(C) Amounts of internalized GFP in PC-3 cells after
treatment with 0.1, 0.5, 1, 5, or 10 mM Ypep-GFP-
Ypep. Values and error bars represent the mean
and SD of three independent experiments.
(D) Fluorescence microscopy image of PC-3 cells
after a 1 hr treatment with 10 mM Ypep-GFP-Ypep
and subsequent washing with PBS containing
20 U/ml heparin sulfate. All images were taken
using a 500 ms exposure. Lamp intensity was set
at 20% for all images.
See also Figures S2, S3, S5, and S8.
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Multivalency Effects Control Cell Uptakecells (Supplemental Experimental Procedures). Cells were then
lysed with a solution previously shown to lyse human cells, but
not phage (Ivanenkov et al., 1999). Phage present in cell lysate
was amplified in Escherichia coli.
In order to remove phage that contain polycationic PTDs,
which would likely penetrate cells nonselectively, or phage that
simply bind the tissue culture plate, phage enriched from the
positive selection were incubated for 1 hr with a vacuum-gas
plasma-treated tissue culture plate, which contains a monolayer
of carboxylic acids on the tissue culture plate surface and is
therefore negatively charged at physiological pH. Only phage
remaining in the solution, and not bound to the culture plate
surface, were enriched. Coupled rounds of positive and negative
selections were performed three times. After the final negative
selection round, enriched phage were amplified in E. coli and
grown as single plaques on an agar plate. Single plaques were
isolated and grown in Luria Broth (LB), and phage was isolated
and precipitated using standard methods. The sequence of
evolved PTDs was identified using standard DNA sequencing
methods. The most abundant sequence enriched from this
selection was ‘‘Ypep’’ (N-YTFGLKTSFNVQ-C); little sequence
homology was observed among the evolved peptide sequences.
Among these enriched peptides, Ypep was determined to be the
most cell-selective and potent PTD.
Determining the Potency of Ypep-GFP Uptake
We prepared a fusion protein consisting of an N-terminal Ypep
sequence, a (GGS)4 linker, and super-folder GFP (sfGFP). This
fusion protein is referred to as ‘‘Ypep-GFP’’ throughout. In
many ways, GFP is an ideal protein to test the characteristics
of a PTD. For example, GFP is simple to express, is stable,
and is easy to image (Tsien, 1998). Although obviously not of
human origin, the molecular weight (27 kDa) and net theoretical
charge at physiological pH (6) of GFP are within the average436 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 Elsevierange among human proteins expressed in E. coli (Cronican
et al., 2011). Like most proteins, wild-type GFP does not pene-
trate human cells (Supplemental Experimental Procedures).
Finally, GFP and its variants, or proteins with similar biophysical
characteristics, have been used for various in vitro and in vivo
bioimaging applications (Filonov et al., 2011; Shaner et al., 2004).
PC-3 cells were treated with 0.5, 1, 5, or 10 mM Ypep-GFP.
Following treatment, this solution was removed, and the cells
were washed with a solution previously shown to remove
surface-bound protein (Cronican et al., 2010, 2011;McNaughton
et al., 2009; Meade and Dowdy, 2008), trypsinized, and assayed
for internalized Ypep-GFP by cytometry. As shown in Figure 2A,
we observed a concentration-dependent increase in Ypep-GFP
levels in PC-3 prostate cancer cells. Flow cytometry data were
collected in three separate experiments; 42- and 86-fold
more cell fluorescence is observed in cells following treatment
with 5 or 10 mM Ypep-GFP, respectively. Fluorescence micros-
copy images show internalized Ypep-GFP in PC-3 cells following
treatment with 10 mM Ypep-GFP (Figure 2B). In contrast, no
appreciable fluorescence was observed in cells treated with
10 mMGFP, thenwashed, and imaged using the same conditions
(Supplemental Experimental Procedures). Taken together, these
data validate the PTD selection.
Determining the Effect Multivalency Has on the Potency
of Ypep-Dependent Delivery
Although we were pleased to observe that a single copy of
Ypep delivers GFP to PC-3 prostate cancer cells, wewere some-
what surprised by the modest potency of cellular uptake. We
reasoned that because selections involve phage, which present
Ypep on the N terminus of five separate copies of phage minor
coat protein 3, multivalent display might be needed in order to
fully realize highly potent Ypep-dependent delivery. Multivalency
effects play critical roles in numerous biological processesr Ltd All rights reserved
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Figure 3. Comparing the Effect Bivalent
Display of Ypep, Tat, and Penetratin Has
on GFP Uptake in PC-3 Cells
(A) Flow cytometry data showing amounts of
internalized GFP in PC-3 cells after treatment with
5 mM Ypep-GFP (blue), penetratin-GFP (green), or
Tat-GFP (red).
(B) Flow cytometry data showing amounts of
internalized GFP in PC-3 cells after treatment with
100 nM Ypep-GFP-Ypep (blue), penetratin-GFP-
penetratin (green), or Tat-GFP-Tat (red). In each
figure, untreated cells are represented in black,
and colored lines represent treated cells.
See also Figure S8.
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Multivalency Effects Control Cell Uptake(Mammen et al., 1998) and have been shown to contribute to the
mechanism of uptake for a previously reported PTD (Moss et al.,
2005). The N termini and C termini of GFP are in close proximity
and have similar directionality (Supplemental Experimental
Procedures). Therefore, GFP is well suited to serve as a protein
scaffold and test the dependency of multivalent effects on
uptake. Toward this end, we prepared a fusion protein with
Ypep on the N termini and C termini of GFP (Ypep-GFP-Ypep).
PC-3 cells were treated with solutions containing 0.1–10 mM
Ypep-GFP-Ypep, were washed with a solution shown to remove
cell-surface-bound protein, were trypsinized from the tissue
culture plate, and internalized GFP levels weremeasured in three
separate experiments by flow cytometry. As shown in Figure 2C,
we observed a concentration-dependent increase in Ypep-GFP-
Ypep delivery in PC-3 cells, with a dramatic increase in the
potency of uptake. This large difference in uptake potency was
confirmed by comparing microscopy images of cells treated
with 10 mM Ypep-GFP (Figure 2B) to cells treated with the
same concentration of Ypep-GFP-Ypep (Figure 2D). A 29-
fold increase in GFP fluorescence was observed in PC-3 cells
treated with 0.5 mM Ypep-GFP-Ypep, compared to PC-3
cells treated with the same concentration of Ypep-GFP. PC-3
cells treated with 0.5 mM Ypep-GFP-Ypep exhibited 3-fold
higher GFP fluorescence compared to cells treated with 5 mM
Ypep-GFP. Precise spatial orientation of Ypep does not appear
to play a prominent role in the potency of uptake, at least in
the context of GFP. A GFP fusion protein containing two copies
of Ypep on the N terminus ((Ypep)2-GFP) has similar potency
of uptake (Supplemental Experimental Procedures). Taken to-
gether, these data suggest an important role for multivalency in
the potency of Ypep-dependent delivery.
Comparing the Effect Bivalent Display of Ypep, Tat, and
Penetratin Has on the Potency of GFP Uptake
Intrigued by the dramatic increase in the potency of GFP uptake
in PC-3 cells, as a result of bivalent display of Ypep, we set out toChemistry & Biology 20, 434–444, March 21, 2013measure if this observation is universal
among commonly used and commercial
PTDs. We prepared GFP fusion proteins
that contain either a single N-terminal
fusion with Tat or penetratin PTDs
(referred to as Tat-GFP and Pen-GFP,
respectively). In addition, we prepared
GFP fusion proteins that contain N- andC-terminal Tat or penetratin (referred to as Tat-GFP-Tat and
Pen-GFP-Pen, respectively). Like Ypep-GFP and Ypep-GFP-
Ypep fusion proteins, in each case, Tat or penetratin is separated
from GFP through a (GGS)4 linker. Polyarginine is a commonly
used PTD (Dubikovskaya et al., 2008); unfortunately, all attempts
to express and purify (Arg)9-GFP and (Arg)9-GFP-(Arg)9 failed.
PC-3 cells were treated with solutions containing 5 mM Ypep-
GFP, Tat-GFP, or Pen-GFP. This concentration was chosen
because it was the lowest concentration that resulted in
relatively high levels of Ypep-GFP delivery. After such time, cells
were washed three times with a PBS solution containing 20 U/ml
heparin sulfate to remove any cell-surface-bound protein. Cells
were trypsinized from the tissue culture plate, and GFP fluores-
cence was measured by flow cytometry. As seen in Figure 3A,
treatment with this concentration of fusion protein resulted in
the delivery of comparatively high levels of Ypep-GFP and Pen-
GFP to PC-3 cells. In contrast, appreciable levels of Tat-GFP
did not penetrate PC-3 cells at the concentration tested. Next,
we incubated PC-3 cells with solutions containing 100 nM
Ypep-GFP-Ypep, Tat-GFP-Tat, or Pen-GFP-Pen. This concen-
tration was chosen because it was the lowest concentration
that resulted in relatively high levels of Ypep-GFP-Ypep delivery.
As shown in Figure 3B, although bivalent display of Ypep resulted
in a 20-fold increase in GFP delivery, the same effect was not
observed for Pen-GFP-Pen and Tat-GFP-Tat fusions. In contrast
to Ypep-GFP-Ypep, bivalent display of penetratin does not
increase uptake. Previous reports have shown that 4–5 copies
of Tat and as many as 10–50 copies of penetratin are required
for a significant increase in the potency of uptake, compared to
the potency of delivery observed for a monomeric fusion (Tseng
et al., 2002). In addition, multivalent dendrimer-PTD conjugates
have been reported to increase potency of uptake compared to
amonovalent species (Li et al., 2009; Sung et al., 2006). However,
these species typically contain >20 copies of the PTD per den-
drimer. In contrast, we observe a dramatic increase in the
potency of delivery for GFP fusions containing two copies ofª2013 Elsevier Ltd All rights reserved 437
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Figure 4. Amounts of Internalized GFP in PC-3, LNCaP, HEK293T,
Hs 697.Sp, and MRC-9 Cells after Treatment with 0.5, 1, or 5 mM
Ypep-GFP
Values and error bars represent the mean and SD of three independent exper-
iments. PC-3, prostate cancer, PSMA-neg; LNCaP, prostate cancer, PSMA-
pos; HEK-293T, kidney; Hs 697.Sp, spleen; MRC-9, lung. See also Figure S8.
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Figure 5. Amounts of Internalized GFP in PC-3, LNCaP, HEK-293T,
Hs 697.Sp, and MRC-9 Cells after Treatment with 0.1, 0.5, 1, or
5 mM Ypep-GFP-Ypep
Values and error bars represent the mean and SD of three independent
experiments. PC-3, prostate cancer, PSMA-neg; LNCaP, prostate cancer,
PSMA-pos; HEK-293T, kidney; Hs 697.Sp, spleen; MRC-9, lung. See also
Figure S8.
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Multivalency Effects Control Cell UptakeYpep. Taken together, these data show the unique role multiva-
lency plays on the potency of Ypep-dependent delivery of GFP.
Determining the Cell Selectivity of Ypep-Dependent
Delivery
Given the role multivalency plays in the potency of Ypep-depen-
dent delivery, we hypothesized that those same effectsmay con-
tribute to the cell selectivity of uptake. We compared the delivery
of Ypep-GFP, Ypep-GFP-Ypep, (Ypep)2-GFP, and (Ypep)5-
phage in PC-3 human prostate cancer cells (PSMA-neg), LNCaP
human prostate cancer cells (PSMA-pos), HEK293T human
embryonic kidney cells, MRC-9 human lung fibroblast cells, and
Hs 697.Sp human spleen fibroblast cells. The potency and cell
selectivity of Ypep-GFP and Ypep-GFP-Ypep delivery was mea-
sured by flow cytometry. Phage titering from cell lysate was used
to compare the amount of internalized phage in each cell line.
Cell Selectivity of Ypep-GFP Delivery
Cells were treated with solutions containing 0.5–5 mMYpep-GFP
and then washed three times with a PBS solution containing
20 U/ml heparin sulfate to remove any cell-surface-bound pro-
tein. After removal from the tissue culture plate, internalized
GFP levels were measured by flow cytometry.
As shown in Figure 4, a single copy of Ypep endows appre-
ciable selectivity of delivery. Following treatment with 5 mM
Ypep-GFP, we observed 4-, 8-, and 5-fold more internal-
ized GFP in targeted PC-3 cells compared to off-target LNCaP,
HEK293T, and Hs 687.Sp cells. High levels of internalized GFP
were found in off-target MRC-9 cells; only 1.4-fold more fluo-
rescence was observed in targeted PC-3 cells. Taken together,
these data demonstrate that monomeric Ypep is moderately
selective for PC-3 cells.
Cell Selectivity of Ypep-GFP-Ypep Delivery
We compared cell penetration of Ypep-GFP-Ypep in PC-3,
LNCaP, HEK293T, MRC-9, and Hs 697.Sp cells. Cells were438 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 Elsevietreated with solutions containing 0.1–5 mM Ypep-GFP-Ypep
and then washed three times with a PBS solution containing
20 U/ml heparin sulfate to remove any cell-surface-bound
protein. Cells were trypsinized from the tissue culture plate,
and cell fluorescence was measured by flow cytometry.
As shown in Figure 5, we observed higher levels of cell
selectivity for Ypep-GFP-Ypep delivery in targeted PC-3 cells,
compared to monomeric Ypep-GFP. Like Ypep-GFP, Ypep-
GFP-Ypep was taken up by targeted PC-3 cells, andmuch lower
levels of internalized GFP was observed in off-target LNCaP,
HEK293T, and Hs 697.Sp cells. However, unlike Ypep-GFP,
which was taken up well in both targeted PC-3 and off-target
MRC-9 cells, Ypep-GFP-Ypep showed a 4-fold preference
for PC-3 cells over MRC-9 cells. Taken together, these data
demonstrate an important role for multivalency in the cell selec-
tivity of delivery.
Cell Selectivity of (Ypep)5-Phage Delivery
We tested the selectivity of (Ypep)5-phage delivery in PC-3,
LNCaP, HEK293, MRC-9, and Hs 697.Sp cells by comparing
the titer of phage from lysate of each cell after incubation and
washing steps. Cells were treated with 5 ml of F12K/10% FBS
containing 1.0 3 109 plaque-forming units (pfu)/ml of (Ypep)5-
phage. This equates to a solution that is 1.7 pM in phage. Thus,
cell penetration at this concentration indicates very high potency.
After incubating the phage with cells, cell-surface-bound phage
was removed, and cells were lysed as described previously. In
addition to titering cell lysate, aliquots from each final washing
solution were titered to ensure that all surface-bound phage
was removed before cell lysis. No phage was found in any of
the final washing solution (Supplemental Experimental Proce-
dures). In contrast, (Ypep)5-phage potently penetrate PC-3
prostate cancer cells (PSMA-neg); high levels of (Ypep)5-phage
plaque-forming units per milliliter (pfu/ml) were found fromr Ltd All rights reserved
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Figure 6. Representative Phage Plaque-Forming Units per Milliliter
Generated from the Cell Lysate of Each Cell Line Tested
The number of plaque-forming units/ml found in each cell lysate is provided
above each bar. See also Figures S4, S5, and S8.
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Multivalency Effects Control Cell UptakePC-3 cell lysate. However, appreciable levels of (Ypep)5-phage
plaques were not observed from the lysate of LNCaP (PSMA-
pos), HEK293T (kidney), Hs 697.Sp (spleen), and MRC-9 (lung)
cells (Figure 6). Experiments were independently performed in
triplicate. Appreciable levels (>25 pfu/ml) of phage were never
observed in E. coli treated with cell lysate from LNCaP (PSMA-
pos), HEK293T (kidney), Hs 697.Sp (spleen), or MRC-9 (lung)
cells. In contrast, in each experiment >1,500 pfu/ml were
observed in E. coli treated with PC-3 cell lysate. Although appre-
ciable, but significantly lower, levels of Ypep-GFP and Ypep-
GFP-Ypep were found in off-target LNCaP and MRC-9 cells,
and much lower levels of (Ypep)5-phage were not found in the
lysate of these off-target cells, compared to targeted PC-3 cells.
This represents a dramatic change in the cell selectivity of Ypep-
dependent delivery. Although these data suggest that multiva-
lency effects likely play a role in the cell selectivity of uptake,
the architecture of Ypep display in the context of fusion to GFP
and fusion to the N terminus of phage coat protein p3 differ
greatly. We cannot rule out the possibility that these architectural
changes may play an important role in the cell selectivity profiles
weobserve. Nonetheless, the cell selectivity andpotency profiles
displayed by bivalent Ypep-GFP fusions and (Ypep)5-phage
make Ypep well suited for targeted bioimaging applications, as
well as phage-based approaches to biomedical science.
Determining the Mechanism of Ypep-GFP, Ypep-GFP-
Ypep, and (Ypep)5-Phage Internalization
The majority of known PTDs have high positive net charge. In
contrast, Ypep has a theoretical net charge of +1. In addition,
we have shown that Ypep displays interesting multivalency-
dependent behavior. Given the characteristics of Ypep, we
were very interested in establishing the mechanism of internali-
zation for Ypep-GFP, Ypep-GFP-Ypep, and (Ypep)5-phage.
Unlike experiments conducted at 37C, cell penetration was
not observed when PC-3 cells were cooled to 4C before and
during treatment with either 15 mM of Ypep-GFP or 10 mM
Ypep-GFP-Ypep (Figures 7B and 7H, respectively). These
results suggest that cell penetration of Ypep-GFP and Ypep-
GFP-Ypep requires an energy-dependent process, consistent
with endocytosis (Meade and Dowdy, 2008). We next evaluated
the cell penetration of each Ypep variant under conditions
that block a particular component of an endocytotic pathway.
PC-3 cells were incubated with relatively high concentrations
of Ypep-GFP or Ypep-GFP-Ypep to assure that changes inChemistry & Biology 20, 4cell fluorescence were due to inhibition of cell penetration as
opposed to relatively small changes in uptake of low concentra-
tions of GFP fusions that may or may not be associated with inhi-
bition of endocytosis. When PC-3 cells were pretreatedwith PBS
containing 5 mg/ml filipin, a small molecule known to inhibit lipid-
raft/caveolae-dependent endocytosis (Schnitzer et al., 1994),
and then incubated with a solution containing 5 mg/ml filipin
and either Ypep-GFP or Ypep-GFP-Ypep, much lower cell fluo-
rescence was observed compared to cells that were not treated
with the inhibitor molecule (Figures 7C and 7I, respectively). In
addition, pretreating cells with 5 mg/ml cytochalasin D, an actin
polymerization inhibitor (May et al., 1998), followed by incubating
those cells with 5 mg/ml cytochalasin D and either Ypep-GFP or
Ypep-GFP-Ypep significantly decreased cell penetration (Fig-
ures 7D and 7J, respectively). In contrast, similar treatment
with 10 mg/ml chlorpromazine, an inhibitor of clathrin-mediated
endocytosis (Wang et al., 1993), had little effect on the efficiency
of cell penetration for both Ypep-GFP and Ypep-GFP-Ypep
(Figures 7E and 7K, respectively). Internalization of caveolae
requires disruption of the local actin cytoskeleton (Head et al.,
2006; Shen and Turner, 2005). Therefore, inhibition of cell pene-
tration as a result of lipid-raft/caveolae-dependent endocytosis
and actin polymerization supports the conclusion that Ypep-
GFP and Ypep-GFP-Ypep penetration of PC-3 cells is mediated
by lipid-raft/caveolae-dependent endocytosis. Internalization
of Ypep-GFP and Ypep-GFP-Ypep is inhibited by 400 mg/ml
heparin sulfate (Figures 7F and 7L, respectively). Based on pre-
vious studies (De Coupade et al., 2005; Mano et al., 2005), this
suggests that internalization requires interaction(s) with one or
more glycosaminoglycans on the surface of PC-3 cells.
We next applied the conditions shown in Figure 7, and
described above, to PC-3 cells treated with (Ypep)5-phage.
Unlike Ypep-GFP and Ypep-GFP fusions, which can be removed
using a relatively simple washing procedure, and for which
internalized protein can be immediately imaged, experiments
with phage require a relatively substantial and lengthy washing
procedure in order to assure that all phage are removed from
the cell surface and only internalized phage are isolated. Unfor-
tunately, following treatment with filipin, cytochalasin D, and
chloropromazine, PC-3 cells did not withstand the washing
protocol. We observed significant loss of cells throughout the
experiment due to cytotoxicity. Therefore, we were unable to
obtain meaningful data from those experiments. Because of
this, studies on the mechanism of (Ypep)5-phage penetration in
PC-3 cells were limited to conditions that were not cytotoxic to
the cells during the course of the experiments.
Unlike experiments conducted at 37C, which yielded high
levels of phage from cell lysate, no phage were isolated when
PC-3 cells were cooled to 4C before and during treatment with
(Ypep)5-phage. This result suggests that cell penetration of
(Ypep)5-phage requires an energy-dependent process, consis-
tent with endocytosis (McNaughton et al., 2009; Meade and
Dowdy, 2008). In addition, internalization of (Ypep)5-phage was
inhibited by heparin sulfate (Supplemental Experimental Proce-
dures), suggesting that internalization requires interaction(s)
with one or more glycosaminoglycans on the surface of PC-3
cells. The ability to significantly decrease or completely abrogate
the levels of Ypep-GFP, Ypep-GFP-Ypep, and (Ypep)5-phage
by suppressing particular endocytotic pathways further supports34–444, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 439
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Figure 7. Mechanistic Probes of Ypep-GFP
and Ypep-GFP-Ypep Internalization
(A) PC-3 cells treated with 15 mM Ypep-GFP
at 37C.
(B) PC-3 cells treated with 15 mM Ypep-GFP
at 4C.
(C) PC-3 cells treated with 15 mM Ypep-GFP at
37C and with 5 mg/ml filipin, a known inhibitor of
lipid-raft/caveolae-mediated endocytosis.
(D) PC-3 cells treated with 15 mM Ypep-GFP at
37C and with 5 mg/ml cytochalasin D, a known
inhibitor of actin polymerization.
(E) PC-3 cells treated with 15 mM Ypep-GFP at
37C and with 15 mg/ml chloropromazine, a known
inhibitor of clathrin-mediated endocytosis.
(F) PC-3 cells treated with 15 mM Ypep-GFP at
37C and with 400 mg/ml heparin sulfate, a
known inhibitor of lipid-raft/caveolae-mediated
endocytosis.
(G–L) The conditions are the same as in Figures
7A–7F, except cells were treatedwith 10 mMYpep-
GFP-Ypep instead of 15 mMYpep-GFP. All images
were obtained using a 200 ms exposure. Lamp
intensity was set at 20% for all images. Scale bars
in each image = 50 mm.
See also Figures S6–S8.
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normal conditions, which lack modulators of endocytosis.
Determining the Cytotoxicity and Robustness
of Ypep-Dependent Delivery
To assess the cytotoxicity of Ypep variants under conditions
required for appreciable uptake, we performed (3-(4,5-Dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT)
on PC-3 cells after treatment with 0.5, 1, or 5 mM Ypep-GFP or
Ypep-GFP-Ypep, or 1.7 pM (Ypep)5-phage. These assays re-
vealed no apparent cytotoxicity to PC-3 cells for any of the
Ypep variants (Supplemental Experimental Procedures).
Phage selections were performed in a complex solution con-
sisting of F12K cell culture media and 10% fetal bovine serum
(FBS). In order for a PTD to be used in vivo, it must penetrate
the target cell in the presence of a complex solution, such as
blood. We treated PC-3 cells with either 10 mM Ypep-GFP or
Ypep-GFP-Ypep in F12K/10% FBS solution containing 50%
human blood. Cells were then washed as described, and red
blood cells were removed using standard methods. Cell fluores-
cence was measured by flow cytometry. Ypep-GFP-Ypep, but
not Ypep-GFP, penetrates PC-3 cells in a solution containing
human blood. In addition, when PC-3 cells were treated with
1.7 pM (Ypep)5-phage in a F12K/10% FBS solution containing
50% human blood, appreciable levels of phage were found
in cell lysate (Supplemental Experimental Procedures). Taken
together, these data suggest that multivalent Ypep-dependent440 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 Elsevier Ltd All rights reservedcell penetration is functional in blood.
The extreme potency of (Ypep)5-phage
cell penetration is not abrogated in the
presence of human blood.
In conclusion, using phage evolu-
tion, we identified a PTD (Ypep) whosepotency and selectivity for targeted PC-3 prostate cancer cells
is tightly controlled through multivalency. When a single copy
of Ypep is attached to the N terminus of GFP (Ypep-GFP), this
fusion protein penetrates a diverse set of human cells with
modest potency and poor cell selectivity. When Ypep is attached
to the N termini and C termini of GFP (Ypep-GFP-Ypep), potency
increases 9- to 29-fold over the same set of human cells, and
cell selectivity increases. Although the same approximate level
of Ypep-GFP is found in PC-3 (PSMA-neg) and MRC-9,
4-foldmoreYpep-GFP-Ypep is found inPC-3 cells over a range
of concentrations. However, phage that display five copies of
Ypep ((Ypep)5-phage) very potently and selectively penetrate
PC-3 cells. When a diverse set of human cells are treated with
media containing 10% FBS solution that is 1.7 pM in (Ypep)5-
phage, these phage penetrate PC-3 cells, but not LNCaP (pros-
tate cancer, PSMA-pos), HEK293T (kidney), Hs 697.Sp (spleen),
and MRC-9 (lung) cells. Collectively, our results reveal Ypep as
a PTD capable of delivering protein (GFP) or nanometer-sized
cargo (phage), with cell-penetrating properties that are tightly
controlled through multivalency effects. Both Ypep-GFP-Ypep
and (Ypep)5-phage penetrate cells in the presence of human
blood. All Ypep-dependent cell penetration is non-cytotoxic at
conditions required for uptake and proceeds via endocytosis.
Both Ypep-GFP and Ypep-GFP-Ypep penetrate PC-3 cells
through caveolae/lipid-raft-mediated endocytosis.
We anticipate that (Ypep)5-phage may be useful as a potent
and robust platform for the targeted delivery of cargo to prostate
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cally engineered to display biopolymer imaging reagents and/or
therapies on various phage coat proteins (p7, p8, and/or p9).
Although functional therapeutic delivery will require release of
phage fromendosomes,phagecanalsobeengineered toorthog-
onally display endosomolytic peptides, which have been shown
to facilitate the disruption of endosomes fromwithin various cells
(Han et al., 2011; Lundberg et al., 2007; Meyer et al., 2008; Oishi
et al., 2007). In addition, given that we observed no obvious
change in themechanismof internalization for eachYpep variant,
identifying the cell surface receptor(s) for Ypep-GFP, Ypep-GFP-
Ypep, and (Ypep)5-phage on PC-3 cells, as well as the sequence
dependence on cellular uptake, will be important for under-
standing thebasis of changes in cell selectivity anduptakepoten-
cies. Progress toward this end will be reported in due course.SIGNIFICANCE
Protein transduction domains (PTDs) offer a straightforward
method for the delivery of biopolymer and nanoscale
reagents to the interior of mammalian cells. Although func-
tionally simple, most PTDs promote general transmembrane
transport and are not cell selective. Cell-selective recogni-
tion is typically achieved through the use of antibody-based
immunoconjugates; however, these reagents are relatively
difficult andexpensive toprepareanddonotdirectly address
the problem of internalization. In this work, we identified a
PTD with uptake, cell selectivity, and potency profiles that
are tightly controlled through multivalency effects. We have
shown that single attachment of Ypep to GFP promotes
uptake of that fusion protein, with relatively modest cell
selectivity and potency. Double fusion of Ypep to the N
termini andC termini of GFP increased the potency of uptake
for that fusion protein to levels beyond those explained by
simple additive effects, suggesting a role for multivalency
in cell uptake of Ypep variants. These bivalent display-
dependent changes in potency and cell selectivity demon-
strated by Ypep were not observed with Tat or penetratin
protein fusions. Phage that display five copies of Ypep on
theN terminusofp3penetrate targetedPC-3prostatecancer
cells with potency and cell selectivity profiles that meet or
exceed those typically associated with antibodies and anti-
body fragments. Collectively, our results reveal Ypep as a
PTD with tunable potency and cell selectivity profiles and
establish (Ypep)5-phage as an extremely potent and cell-
selective PTD platform capable of delivering an imaging
reagent protein (GFP) and nanoscale reagents (phage) to
a malignant prostate cancer cell line that is not susceptible
to PSMA-targeted prostate-cancer-targeted therapeutic
delivery platforms. Our investigations reported in this paper
are a starting point for the optimization of genetically engi-
neered (Ypep)5-phage for use in PC-3 cell-targeted bio-
polymer and nanoscale therapeutic and imaging delivery.EXPERIMENTAL PROCEDURES
Materials
PBS, 0.25% trypsin, Dulbecco’s modified Eagle’s medium (DMEM),
RPMI-1640 medium, B-PER Bacterial Protein Extraction Reagent, a ModifiedChemistry & Biology 20, 4Lowry Protein Assay Kit, and a Pierce Firefly Luciferase Glow Assay Kit were
purchased from Thermo Scientific (Waltham, MA, USA). Cellgro F-12K
medium was purchased from MediaTech (Manassas, VA, USA). Fetal
bovine serum (FBS) was purchased from PAA Laboratories (Westborough,
MA, USA). cOmplete Mini Protease Inhibitor Cocktail Tablets were pur-
chased from Roche (Indianapolis, IN, USA). TACS MTT reagent was
purchased from Trevigen (Gaithersburg, MD, USA). The Ph.D.-12 Phage
Display Library, Nco I HF, and KpnI HF were purchased from New
England Biolabs (NEB) (Ipswich, MA, USA). Sodium deoxycholate, heparin
sulfate, and imidazole were purchased from Sigma-Aldrich (St. Louis).
Ni-NTA agarose resin was purchased from QIAGEN (Hilden, Germany).
Lowry protein assay was purchased from Pierce Biotechnology (Rockford,
IL, USA). Human blood was purchased from Innovative Research (Novi,
MI, USA).
Instrumentation
Fluorescence microscopy images were taken on an EVOS fluorescence
inverted microscope from the Advanced Microscopy Group (AMG). MTT
assay readings were taken on a Synergy Mx microplate reader from
BioTek Instruments (Winooski, VT, USA). Flow cytometry experiments
were performed on a MoFlo (Dako Colorado, Fort Collins, CO, USA) flow
cytometer using a solid-state iCyt 488 nm (blue) laser to measure GFP
fluorescence.
Mammalian Cell Culture
Human prostate adenocarcinoma cells (PC-3) cells were cultured in F12K with
10% fetal bovine serum (FBS). Human prostate carcinoma cells (LNCaP) and
human embryonic lung fibroblasts (MRC-9) cells were cultured in RPMI-1640
media with 10% FBS; human spleen fibroblasts (Hs 697.Sp) and HEK293T
cells were cultured in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS). PC-3, LNCaP, and MRC-9 cells
were incubated at 37Cwith 5%CO2 environment. Hs 697.Sp cells were incu-
bated at 37C with 10% CO2 environment. All cells were obtained from the
American Type Culture Collection.
Phage Selection
Positive Selection
A 10 ml solution of F12K/10% FBS containing 531010 phage library members
(Ph.D.-12 Phage Display Library, NEB) was added to 80% confluent PC-3
cells grown as a monolayer in a T25 culture flask and incubated at 37C under
5% CO2 environment for 3 hr. After incubation, cells were then placed on ice
for 5 min and washed with 4C PBS five times while on ice. Cells were then
washed three times with 4C Tris-buffered saline (TBS)/0.1% v/v Tween-20
for 3 min each while on ice. The remaining surface-bound phage was proteo-
lyzed by addition of a 5 ml TBS/subtilisin (3 mg/ml) for 45 min at 4C. Cells
were then transferred into a 15 ml plastic tube and pelleted for 5 min at
3,000 rpm and at 4C. Supernatant was removed, and cells were resus-
pended in 5 ml PBS/5 ml protease inhibitor for 15 min at 4C and then pelleted
for 5 min at 3,000 rpm and 4C. Supernatant was removed, and cells were
resuspended in 1 ml of PBS and pelleted for 5 min at 3,000 rpm and 4C.
Supernatant was removed and saved as the last wash solution for subse-
quent titering. Cells were lysed with 0.5 ml of lysis buffer (2% sodium deox-
ycholate, 10 mM Tris-HCl, and 2 mM EDTA) and 0.5 ml of TBS for 1 hr at
room temperature. After cell lysis, internalized phage was amplified in
a 150 ml flask containing 30 ml LB, 360 ml 0.1 M CaCl2, 20 mg/ml tetracycline,
and 0.15 ml of E. coli (ER2837) that had been grown to optical density
(OD)z0.5. The final wash solution (200 ml) or the cell lysate was then added,
and this solution was incubated at 37C, 250 rpm for 5 hr. E. coli was pelleted
for 10 min at 10,000 rpm and 4C. Supernatant containing phage was trans-
ferred to another tube, and E. coli cell debris was pelleted at 10,000 rpm for
10 min at 4C. Phage from the supernatant was precipitated by addition of
5 ml 20% PEG-8000/2.5 M NaCl. Phage was only amplified after positive
selection rounds; the phage-containing media from negative selections was
directly added to positive cell lines without amplification of the phage. Nega-
tive selection: A 10 ml solution containing 109 pfu/ml amplified from the posi-
tive selection was added to a T25 culture flask and incubated at 37C with
5% CO2 environment for 1 hr. Rounds of positive and negative selection
were performed three times.34–444, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 441
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All constructs were cloned into pET plasmids. DNAs encoding cell-penetrating
peptide fusions with sfGFP were assembled using oligonucleotide overlap
gene construction and PCR.
Protein Purification
BL21-DE3 E. coli were typically grown in 500 ml LB cultures at 37C to OD600
z0.6 and induced with 1 mM IPTG at 30C overnight. Cells were then pelleted
by centrifugation and lysedwith 25ml B-PER. Cell lysatewas cleared by centri-
fugation (17,000 rpm, 30 min), and supernatant was mixed with 1 ml of Ni-NTA
agarose resin for 1 hr at 4C under agitation. Resin was collected by centrifu-
gation (4,950 rpm, 10 min). Ni-NTA agarose resin was washed with 50 ml of
PBS containing 300 mM NaCl and then 50 ml of PBS containing 20 mM
imidazole. Protein was then eluted with 5 ml PBS containing 300 mM NaCl
and 500 mM imidazole. Eluted protein was dialyzed against PBS and analyzed
for purity by SDS-PAGE followed by staining with Coomassie Blue. Protein
concentrations were measured using a modified Lowry Protein Assay Kit.
Flow Cytometry
Mammalian cells were grown to80% confluency in a 6-well plate. Cells were
washed once with PBS and PBS containing Ypep-GFP, (Ypep)2-GFP, or
Ypep-GFP-Ypep was added. Cells were incubated with each PBS/protein
solution for 3 hr at 37C under 5% CO2 environment and then washed twice
with PBS and three times with PBS-HS (heparin sulfate 20 U/ml) for 10 min
each at 37C.Cells were then removed from the tissue culture plate by addition
of 0.5 ml of 0.25% trypsin and pelleted by centrifugation. Cell pellet was resus-
pended in PBS/10% FBS, and cell fluorescence was analyzed by flow
cytometry.
Mechanism of Cell Penetration
PC-3 cells were grown to 80% confluency in a 12-well tissue culture plate.
Cells were then washed once with PBS and incubated with the small molecule
inhibitor in PBS for 10 min at 37C under 5% CO2 environment. The PBS-
small-molecule solution was then removed, and a PBS solution containing
either 15 mM Ypep-GFP or 10 mM Ypep-GFP-Ypep with a small molecule
inhibitor in PBS was added to the cells. Cells were incubated in each solution
for 30 min at 37C under 5% CO2 environment. Cells were washed twice with
PBS, once with PBS-HS (heparin sulfate 20 U/ml), and imaged on an EVOS fl
fluorescence microscope.
Cell Selectivity Experiments
For experiments involving Ypep-GFP and Ypep-GFP-Ypep, cell penetra-
tion was measured using flow cytometry, as described above (see Flow
Cytometry). For cell selectivity experiments involving (Ypep)5-phage, cells
were grown to 80% confluency and then treated with 5 ml of media supple-
mented with 10% FBS and 13 109 pfu/ml (Ypep)5-phage for 3 hr at 37
C and
5% CO2 environment. Cells were washed and lysed as previously described
(see Phage Selection). An aliquot of the final wash solutionwas kept for titering.
Following cell lysis (see Phage Selection), aliquots from cell lysate and the last
wash before lysis were titered. Titering was carried out as described above
(see Phage Selection). After this time, the entire E. coli mixture was plated
on IPTG/X-gal LB-agar plates and incubated at 37C for 18 hr.
MTT Cell Viability Assay
Assays were performed following the provided instructions. Briefly, PC-3 cells
were grown to 80% confluency in a 12-well tissue culture plate. Cells were
then washed once with PBS and incubated with 0.5–5 mM Ypep-GFP or
Ypep-GFP-Ypep in PBS for 3 hr at 37C under a 5% CO2 environment. Cells
were washed three times with PBS-HS (20 U/ml heparin sulfate) and then
incubated with 0.5 ml media containing 25 ml of MTT reagent for 4.5 hr. After
such time, a 250 ml detergent reagent was added to the cells, and they were
incubated for an additional 30 min at 37C under a 5% CO2 environment.
Absorbance was measured at 570 nm on a Synergy Mx microplate reader.
Cell viability of cells treated with (Ypep)5-phage was determined after a 3 hr
incubation with 5 ml of 13 109 pfu/ml Ypep-phage (1.67 pM) in F12K medium
supplementedwith 10%FBS at 37Cunder a 5%CO2 environment. PC-3 cells
were washed twice with PBS, and the MTT assay was performed as described
above.442 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 ElsevieYpep-GFP and Ypep-GFP-Ypep Internalization in the Presence
of Human Blood
PC-3 cells were grown to80% confluency in a 6-well plate. Whole blood was
diluted in half with F12K/10% FBS. To this solution either Ypep-GFP or Ypep-
GFP-Ypep was added to final concentrations of 10 mM. Cells were incubated
with these solutions for 1 hr, washed once with PBS, and then washed
twice with a red blood cell lysis buffer (0.15 M NH4Cl, 0.01 M KHCO3, and
0.0001 M EDTA [pH = 7.7]) to remove all red blood cells. Cells were washed
three times with PBS-HS (20 U/ml heparin sulfate) and imaged on an EVOS
fl fluorescence microscope.
(Ypep)5-Phage Internalization in the Presence of Human Blood
PC-3 cells were grown to80% confluency in a 6-well plate. Whole blood was
diluted in half with F12K/10% FBS. To this solution, 1 3 109 (Ypep)5-phage
(1.67 pM) was added. Cells were incubated in this solution for 3 hr at 37C
under a 5% CO2 environment. Cells were washed twice with red blood cell
lysis buffer, twice with PBS, and three times with Tris-buffered saline (TBS)/
0.1% v/v Tween-20 for 3 min each on ice. Cells were then washed as
described. Aliquots from final wash and cell lysate solutions were titered as
described previously (see Phage Selection: Positive Selection).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2013.01.015.
ACKNOWLEDGMENTS
This work was supported in part by institutional funds provided by Colorado
State University and the Department of Defense (CDMRP Prostate Cancer
New Innovator Award). We thank Professor Alan J. Kennan (Colorado State
University) for helpful comments.
Received: August 15, 2012
Revised: January 8, 2013
Accepted: January 31, 2013
Published: March 21, 2013
REFERENCES
Boisselier, E., and Astruc, D. (2009). Gold nanoparticles in nanomedicine:
preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev.
38, 1759–1782.
Bostwick, D.G., Pacelli, A., Blute, M., Roche, P., and Murphy, G.P. (1998).
Prostate specific membrane antigen expression in prostatic intraepithelial
neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261.
Cronican, J.J., Thompson, D.B., Beier, K.T., McNaughton, B.R., Cepko, C.L.,
and Liu, D.R. (2010). Potent delivery of functional proteins into mammalian
cells in vitro and in vivo using a supercharged protein. ACS Chem. Biol. 5,
747–752.
Cronican, J.J., Beier, K.T., Davis, T.N., Tseng, J.C., Li, W.D., Thompson, D.B.,
Shih, A.F., May, E.M., Cepko, C.L., Kung, A.L., et al. (2011). A class of human
proteins that deliver functional proteins into mammalian cells in vitro and
in vivo. Chem. Biol. 18, 833–838.
Dassie,J.P.,Liu,X.Y.,Thomas,G.S.,Whitaker,R.M.,Thiel,K.W.,Stockdale,K.R.,
Meyerholz, D.K., McCaffrey, A.P., McNamara, J.O., 2nd, and Giangrande, P.H.
(2009). Systemic administration of optimized aptamer-siRNA chimeras pro-
motes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839–849.
DeCoupade, C., Fittipaldi, A., Chagnas, V., Michel, M., Carlier, S., Tasciotti, E.,
Darmon, A., Ravel, D., Kearsey, J., Giacca, M., and Cailler, F. (2005). Novel
human-derived cell-penetrating peptides for specific subcellular delivery of
therapeutic biomolecules. Biochem. J. 390, 407–418.
Derossi, D., Joliot, A.H., Chassaing, G., and Prochiantz, A. (1994). The third
helix of the Antennapedia homeodomain translocates through biological
membranes. J. Biol. Chem. 269, 10444–10450.r Ltd All rights reserved
Chemistry & Biology
Multivalency Effects Control Cell UptakeDeshayes, S., Morris, M.C., Divita, G., and Heitz, F. (2005). Cell-penetrating
peptides: tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci.
62, 1839–1849.
Dubikovskaya, E.A., Thorne, S.H., Pillow, T.H., Contag, C.H., and Wender,
P.A. (2008). Overcoming multidrug resistance of small-molecule therapeutics
through conjugation with releasable octaarginine transporters. Proc. Natl.
Acad. Sci. USA 105, 12128–12133.
Filonov, G.S., Piatkevich, K.D., Ting, L.M., Zhang, J.H., Kim, K., and
Verkhusha, V.V. (2011). Bright and stable near-infrared fluorescent protein
for in vivo imaging. Nat. Biotechnol. 29, 757–761.
Ford, K.G., Souberbielle, B.E., Darling, D., and Farzaneh, F. (2001). Protein
transduction: an alternative to genetic intervention? Gene Ther. 8, 1–4.
Frankel, A.D., and Pabo, C.O. (1988). Cellular uptake of the tat protein from
human immunodeficiency virus. Cell 55, 1189–1193.
Fuchs, S.M., and Raines, R.T. (2005). Polyarginine as a multifunctional fusion
tag. Protein Sci. 14, 1538–1544.
Gabel, C.A., and Foster, S.A. (1986). Mannose 6-phosphate receptor-
mediated endocytosis of acid hydrolases: internalization of beta-glucuroni-
dase is accompanied by a limited dephosphorylation. J. Cell Biol. 103,
1817–1827.
Gao, C., Mao, S., Ditzel, H.J., Farnaes, L., Wirsching, P., Lerner, R.A., and
Janda, K.D. (2002). A cell-penetrating peptide from a novel pVII-pIX phage-
displayed random peptide library. Bioorg. Med. Chem. 10, 4057–4065.
Ghosh, A., Wang, X., Klein, E., and Heston, W.D.W. (2005). Novel role of pros-
tate-specific membrane antigen in suppressing prostate cancer invasiveness.
Cancer Res. 65, 727–731.
Ghosh, D., Lee, Y., Thomas, S., Kohli, A.G., Yun, D.S., Belcher, A.M., and Kelly,
K.A. (2012). M13-templated magnetic nanoparticles for targeted in vivo
imaging of prostate cancer. Nat. Nanotechnol. 7, 677–682.
Green, M., and Loewenstein, P.M. (1988). Autonomous functional domains of
chemically synthesized human immunodeficiency virus tat trans-activator
protein. Cell 55, 1179–1188.
Gregoriadis, G. (1995). Engineering liposomes for drug delivery: progress and
problems. Trends Biotechnol. 13, 527–537.
Han, M., Kickhoefer, V.A., Nemerow, G.R., and Rome, L.H. (2011). Targeted
vault nanoparticles engineered with an endosomolytic peptide deliver bio-
molecules to the cytoplasm. ACS Nano 5, 6128–6137.
Head, B.P., Patel, H.H., Roth, D.M., Murray, F., Swaney, J.S., Niesman, I.R.,
Farquhar, M.G., and Insel, P.A. (2006). Microtubules and actin microfilaments
regulate lipid raft/caveolae localization of adenylyl cyclase signaling com-
ponents. J. Biol. Chem. 281, 26391–26399.
Henry, M.D., Wen, S.H., Silva, M.D., Chandra, S., Milton, M., andWorland, P.J.
(2004). A prostate-specific membrane antigen-targeted monoclonal antibody-
chemotherapeutic conjugate designed for the treatment of prostate cancer.
Cancer Res. 64, 7995–8001.
Hughes, B. (2010). Antibody-drug conjugates for cancer: poised to deliver?
Nat. Rev. Drug Discov. 9, 665–667.
Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R., and Heston, W.D. (1994).
Expression of the prostate-specific membrane antigen. Cancer Res. 54,
1807–1811.
Ivanenkov, V., Felici, F., and Menon, A.G. (1999). Uptake and intracellular
fate of phage display vectors in mammalian cells. Biochim. Biophys. Acta
1448, 450–462.
Kim, Y., Lillo, A.M., Steiniger, S.C., Liu, Y., Ballatore, C., Anichini, A., Mortarini,
R., Kaufmann, G.F., Zhou, B., Felding-Habermann, B., and Janda, K.D. (2006).
Targeting heat shock proteins on cancer cells: selection, characterization, and
cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 45,
9434–9444.
Lapidus, R.G., Tiffany, C.W., Isaacs, J.T., and Slusher, B.S. (2000). Prostate-
specific membrane antigen (PSMA) enzyme activity is elevated in prostate
cancer cells. Prostate 45, 350–354.
Leader, B., Baca, Q.J., and Golan, D.E. (2008). Protein therapeutics:
a summary and pharmacological classification. Nat. Rev. Drug Discov. 7,
21–39.Chemistry & Biology 20, 4Li, S.Z., McGuire, M.J., Lin, M., Liu, Y.H., Oyama, T., Sun, X.K., and Brown,
K.C. (2009). Synthesis and characterization of a high-affinity alphavbeta6-
specific ligand for in vitro and in vivo applications. Mol. Cancer Ther. 8,
1239–1249.
Lundberg, P., El-Andaloussi, S., Su¨tlu¨, T., Johansson, H., and Langel, U.
(2007). Delivery of short interfering RNA using endosomolytic cell-penetrating
peptides. FASEB J. 21, 2664–2671.
Ma¨e, M., and Langel, U. (2006). Cell-penetrating peptides as vectors for
peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 6,
509–514.
Mammen, M., Choi, S.K., andWhitesides, G.M. (1998). Polyvalent interactions
in biological systems: implications for design and use of multivalent ligands
and inhibitors. Angew. Chem. Int. Ed. 37, 2755–2794.
Mano, M., Teodo´sio, C., Paiva, A., Simo˜es, S., and Pedroso de Lima, M.C.
(2005). On the mechanisms of the internalization of S4(13)-PV cell-penetrating
peptide. Biochem. J. 390, 603–612.
May, J.A., Ratan, H., Glenn, J.R., Lo¨sche, W., Spangenberg, P., and
Heptinstall, S. (1998). GPIIb-IIIa antagonists cause rapid disaggregation of
platelets pre-treated with cytochalasin D. Evidence that the stability of platelet
aggregates depends on normal cytoskeletal assembly. Platelets 9, 227–232.
McGregor, D.P. (2008). Discovering and improving novel peptide therapeutics.
Curr. Opin. Pharmacol. 8, 616–619.
McNaughton, B.R., Cronican, J.J., Thompson, D.B., and Liu, D.R. (2009).
Mammalian cell penetration, siRNA transfection, and DNA transfection by
supercharged proteins. Proc. Natl. Acad. Sci. USA 106, 6111–6116.
Meade, B.R., and Dowdy, S.F. (2008). Enhancing the cellular uptake of siRNA
duplexes following noncovalent packaging with protein transduction domain
peptides. Adv. Drug Deliv. Rev. 60, 530–536.
Meyer, M., Philipp, A., Oskuee, R., Schmidt, C., and Wagner, E. (2008).
Breathing life into polycations: functionalization with pH-responsive endo-
somolytic peptides and polyethylene glycol enables siRNA delivery. J. Am.
Chem. Soc. 130, 3272–3273.
Moss, J.A., Lillo, A., Kim, Y.S., Gao, C.S., Ditzel, H., and Janda, K.D. (2005). A
dimerization ‘‘switch’’ in the internalization mechanism of a cell-penetrating
peptide. J. Am. Chem. Soc. 127, 538–539.
Murphy, G.P., Elgamal, A.A.A., Su, S.L., Bostwick, D.G., and Holmes, E.H.
(1998). Current evaluation of the tissue localization and diagnostic utility of
prostate specific membrane antigen. Cancer 83, 2259–2269.
Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Smith-Jones, P.M.,
Vallabahajosula, S., Goldsmith, S.J., and Bander, N.H. (2003). Clinical use of
monoclonal antibody HuJ591 therapy: targeting prostate specific membrane
antigen. J. Urol. 170, S84–S88, discussion S88–S89.
Nomura, T., Kawamura, M., Shibata, H., Abe, Y., Ohkawa, A., Mukai, Y.,
Sugita, T., Imai, S., Nagano, K., Okamoto, T., et al. (2007). Creation of a novel
cell penetrating peptide, using a random 18mer peptides library. Pharmazie
62, 569–573.
Oishi, M., Hayashi, H., Itaka, K., Kataoka, K., and Nagasaki, Y. (2007).
pH-responsive PEGylated nanogels as targetable and low invasive endoso-
molytic agents to induce the enhanced transfection efficiency of nonviral
gene vectors. Colloid Polym. Sci. 285, 1055–1060.
Patri, A.K., Myc, A., Beals, J., Thomas, T.P., Bander, N.H., and Baker, J.R., Jr.
(2004). Synthesis and in vitro testing of J591 antibody-dendrimer conjugates
for targeted prostate cancer therapy. Bioconjug. Chem. 15, 1174–1181.
Pulukuri, S.M., Gondi, C.S., Lakka, S.S., Jutla, A., Estes, N., Gujrati, M., and
Rao, J.S. (2005). RNA interference-directed knockdown of urokinase plasmin-
ogen activator and urokinase plasminogen activator receptor inhibits prostate
cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280,
36529–36540.
Rizk, S.S., Luchniak, A., Uysal, S., Brawley, C.M., Rock, R.S., and Kossiakoff,
A.A. (2009). An engineered substance P variant for receptor-mediated delivery
of synthetic antibodies into tumor cells. Proc. Natl. Acad. Sci. USA 106, 11011–
11015.
Schnitzer, J.E., Oh, P., Pinney, E., and Allard, J. (1994). Filipin-sensitive caveo-
lae-mediated transport in endothelium: reduced transcytosis, scavenger34–444, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 443
Chemistry & Biology
Multivalency Effects Control Cell Uptakeendocytosis, and capillary permeability of select macromolecules. J. Cell Biol.
127, 1217–1232.
Shaner, N.C., Campbell, R.E., Steinbach, P.A., Giepmans, B.N.G., Palmer,
A.E., and Tsien, R.Y. (2004). Improvedmonomeric red, orange and yellow fluo-
rescent proteins derived from Discosoma sp. red fluorescent protein. Nat.
Biotechnol. 22, 1567–1572.
Shen, L., and Turner, J.R. (2005). Actin depolymerization disrupts tight
junctions via caveolae-mediated endocytosis. Mol. Biol. Cell 16, 3919–3936.
Sung, M., Poon, G.M., and Garie´py, J. (2006). The importance of valency in
enhancing the import and cell routing potential of protein transduction
domain-containing molecules. Biochim. Biophys. Acta 1758, 355–363.
Thorek, D.L.J., Chen, A.K., Czupryna, J., and Tsourkas, A. (2006).
Superparamagnetic iron oxide nanoparticle probes for molecular imaging.
Ann. Biomed. Eng. 34, 23–38.
Torchilin, V.P., and Lukyanov, A.N. (2003). Peptide and protein drug delivery to
and into tumors: challenges and solutions. Drug Discov. Today 8, 259–266.444 Chemistry & Biology 20, 434–444, March 21, 2013 ª2013 ElsevieTseng, Y.L., Liu, J.J., and Hong, R.L. (2002). Translocation of liposomes into
cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and effi-
cacy study. Mol. Pharmacol. 62, 864–872.
Tsien, R.Y. (1998). The green fluorescent protein. Annu. Rev. Biochem. 67,
509–544.
Wang, L.H., Rothberg, K.G., and Anderson, R.G.W. (1993). Mis-assembly of
clathrin lattices on endosomes reveals a regulatory switch for coated pit
formation. J. Cell Biol. 123, 1107–1117.
Wright, G.L., Jr., Haley, C., Beckett, M.L., and Schellhammer, P.F. (1995).
Expression of prostate-specific membrane antigen in normal, benign, and
malignant prostate tissues. Urol. Oncol. 1, 18–28.
Wu, A.M., and Senter, P.D. (2005). Arming antibodies: prospects and chal-
lenges for immunoconjugates. Nat. Biotechnol. 23, 1137–1146.
Zelphati, O., Wang, Y., Kitada, S., Reed, J.C., Felgner, P.L., and Corbeil, J.
(2001). Intracellular delivery of proteins with a new lipid-mediated delivery
system. J. Biol. Chem. 276, 35103–35110.r Ltd All rights reserved
